文献速递类风湿关节炎脊柱关节炎

类风湿关节炎与银屑病关节炎患者接受TNF抑制剂治疗期间严重感染风险比较:NOR-DMARD研究登记联动数据

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
PubMed 文献 · Ann Rheum Dis · 2021-10-08

基于NOR-DMARD登记联动数据,纳入2359例患者共3169个TNFi治疗疗程(RA 1778个、PsA 1391个),比较RA与PsA患者严重感染(SI)风险。完全集分析中PsA较RA的SI风险显著更低(HR 0.59,95%CI 0.41–0.85,p=0.004),多因素调整后仍显著且在各年龄、性别和疾病状态分层中一致。

要点

  • 完全集分析中PsA较RA严重感染风险显著降低(HR 0.59,95%CI 0.41–0.85,p=0.004)。
  • 多因素调整后PsA风险降低仍显著,且在各年龄、性别和疾病状态分层中一致。

核心结论

  • 与RA患者相比,PsA患者在TNFi暴露期间严重感染风险显著更低。

研究设计与样本

  • 基于NOR-DMARD登记联动数据,纳入开始TNFi治疗的RA和PsA患者,共2359例患者、3169个治疗疗程(RA 1778个、PsA 1391个)。
  • 计算严重感染粗发病率和发病率比,并用校正Cox回归模型比较RA与PsA的严重感染风险。

主要发现

  • RA患者严重感染粗发病率为4.17(95%CI 3.52–4.95),PsA患者为2.16(95%CI 1.66–2.81)。
  • 完全集分析中,与RA相比,PsA的严重感染风险降低(HR 0.59,95%CI 0.41–0.85,p=0.004)。
  • PsA较RA的风险降低在多因素调整后仍显著,且在年龄、性别和疾病状态分层中一致。

关键数值与推荐

  • RA患者严重感染粗发病率4.17(95%CI 3.52–4.95),PsA患者2.16(95%CI 1.66–2.81)。
  • 完全集分析中PsA vs RA的严重感染HR 0.59(95%CI 0.41–0.85,p=0.004)。

临床怎么用

  • 临床评估TNFi治疗严重感染风险时,应考虑RA与PsA的基线风险差异。
  • RA患者TNFi治疗期间可能需更关注严重感染监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the incidence of serious infections (SIs) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with tumour necrosis factor inhibitor (TNFi), and compare risk of SIs between patients with RA and PsA. METHODS: We included patients with RA and PsA from the NORwegian-Disease Modifying Anti-Rheumatic Drug registry starting TNFi treatment. Crude incidence rates (IRs) and IR ratio for SIs were calculated. The risk of SIs in patients with RA and PsA was compared using adjusted Cox-regression models. RESULTS: A total of 3169 TNFi treatment courses (RA/PsA: 1778/1391) were identified in 2359 patients. Patients with RA were significantly older with more extensive use of co-medication. The crude IRs for SIs were 4.17 (95% CI 3.52 to 4.95) in patients with RA and 2.16 (95% CI 1.66 to 2.81) in patients with PsA. Compared with the patients with RA, patients with PsA had a lower risk of SIs (HR 0.59, 95% CI 0.41 to 0.85, p=0.004) in complete set analysis. The reduced risk in PsA versus RA remained significant after multiple adjustments and consistent across strata based on age, gender and disease status. CONCLUSIONS: Compared with patients with RA, the risk of SIs was significantly lower in patients with PsA during TNFi exposure.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Christensen IE, Lillegraven S, Mielnik P, et al. Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. Ann Rheum Dis. 2021. PMID: 34625404. doi:10.1136/annrheumdis-2021-221007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。